{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -2.36, "epsForward": -4.6, "epsCurrentYear": -11.42, "priceEpsCurrentYear": -0.06558669, "sharesOutstanding": 2264960, "bookValue": 1.288, "fiftyDayAverage": 1.93708, "fiftyDayAverageChange": -1.1880801, "fiftyDayAverageChangePercent": -0.61333555, "twoHundredDayAverage": 7.81824, "twoHundredDayAverageChange": -7.06924, "twoHundredDayAverageChangePercent": -0.9041984, "marketCap": 1857490, "forwardPE": -0.16282609, "priceToBook": 0.58152175, "currency": "USD", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "PRE", "regularMarketChangePercent": -2.7272687, "regularMarketPrice": 0.749, "firstTradeDateMilliseconds": 1644589800000, "priceHint": 4, "exchange": "NCM", "shortName": "TC BioPharm (Holdings) plc", "longName": "TC Biopharm (Holdings) Plc", "messageBoardId": "finmb_1681274131", "regularMarketChange": -0.020999968, "regularMarketTime": 1684180778, "regularMarketDayHigh": 0.7978, "regularMarketDayRange": "0.71 - 0.7978", "regularMarketDayLow": 0.71, "regularMarketVolume": 175831, "regularMarketPreviousClose": 0.77, "bid": 0.0, "ask": 0.0, "bidSize": 10, "askSize": 13, "fullExchangeName": "NasdaqCM", "financialCurrency": "GBP", "regularMarketOpen": 0.7699, "averageDailyVolume3Month": 315103, "averageDailyVolume10Day": 345000, "fiftyTwoWeekLowChange": 0.039000034, "fiftyTwoWeekLowChangePercent": 0.05492963, "fiftyTwoWeekRange": "0.71 - 70.0", "fiftyTwoWeekHighChange": -69.251, "fiftyTwoWeekHighChangePercent": -0.9893, "fiftyTwoWeekLow": 0.71, "fiftyTwoWeekHigh": 70.0, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2022-02-11", "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "displayName": "TC Biopharm (Holdings)", "symbol": "TCBP"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Maxim 1", "address2": "2 Parklands Way Holytown", "city": "Motherwell", "zip": "ML1 4WR", "country": "United Kingdom", "phone": "44 14 1433 7557", "website": "https://www.tcbiopharm.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.", "fullTimeEmployees": 60, "companyOfficers": [{"maxAge": 1, "name": "Mr. Bryan L. Kobel", "age": 41, "title": "CEO & Director", "yearBorn": 1981, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Martin E. Thorp", "age": 70, "title": "CFO & Director", "yearBorn": 1952, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Christopher  Camarra", "title": "Exec. VP of Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Bree  Harlin", "title": "Chief Clinical Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "maxAge": 86400}}], "error": null}}